Biblio
“5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 573-585, 2022.
, “Antihypertensive Medication Class and the Risk of Dementia and Cognitive Decline in Older Adults: A Secondary Analysis of the Prospective HELIAD Cohort.”, J Alzheimers Dis, vol. 89, no. 2, pp. 709-719, 2022.
, “Anti-Inflammatory Gene Therapy Improves Spatial Memory Performance in a Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1001-1008, 2022.
, “Association Between Serum Vitamins and the Risk of Alzheimer's Disease in Chinese Population.”, J Alzheimers Dis, vol. 85, no. 2, pp. 829-836, 2022.
, “Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1267-1282, 2022.
, “"Captive by the Uncertainty"-Experiences with Anticipatory Guidance for People Living with Dementia and Their Caregivers at a Specialty Dementia Clinic.”, J Alzheimers Dis, vol. 86, no. 2, pp. 787-800, 2022.
, “Caregiver Tele-Assistance for Reduction of Emotional Distress During the COVID-19 Pandemic. Psychological Support to Caregivers of People with Dementia: The Italian Experience.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1045-1052, 2022.
, “Cognitive Decline Risk Stratification in People with Late-Onset Epilepsy of Unknown Etiology: An Electroencephalographic Connectivity and Graph Theory Pilot Study.”, J Alzheimers Dis, vol. 88, no. 3, pp. 893-901, 2022.
, “A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 691-699, 2022.
, “The Correlation of Tau Levels with Blood Monocyte Count in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1321-1328, 2022.
, “Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 1, pp. 443-456, 2022.
, “Impact of COVID-19 on 'Living Well' with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort.”, J Alzheimers Dis, vol. 85, no. 2, pp. 925-940, 2022.
, “Oral Health Status in Subjects with Amnestic Mild Cognitive Impairment and Alzheimer's Disease: Data from the Zabút Aging Project.”, J Alzheimers Dis, vol. 87, no. 1, pp. 173-183, 2022.
, “Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging.”, J Alzheimers Dis, vol. 89, no. 3, pp. 943-954, 2022.
, “Risk of Alzheimer's Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching.”, J Alzheimers Dis, vol. 88, no. 3, pp. 1061-1074, 2022.
, “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
, “Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model.”, J Alzheimers Dis, vol. 85, no. 2, pp. 755-778, 2022.
, “ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.”, J Alzheimers Dis, vol. 79, no. 1, pp. 423-431, 2021.
, “APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 79, no. 2, pp. 511-530, 2021.
, “Automatic Subtyping of Individuals with Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1185-1194, 2021.
, “The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation.”, J Alzheimers Dis, vol. 81, no. 4, pp. 1505-1527, 2021.
, “Cannabidiol Ameliorates Cognitive Function via Regulation of IL-33 and TREM2 Upregulation in a Murine Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 80, no. 3, pp. 973-977, 2021.
, “Cognition at Each Stage of Lewy Body Disease with Co-occurring Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 80, no. 3, pp. 1243-1256, 2021.
, “Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial.”, J Alzheimers Dis, vol. 83, no. 4, pp. 1703-1715, 2021.
, “Combining Multimodal Behavioral Data of Gait, Speech, and Drawing for Classification of Alzheimer's Disease and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 84, no. 1, pp. 315-327, 2021.
,